Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017-02-20
Future Challenges for Drug Development in Renal Cell Carcinoma.
Related Questions
The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib.
New answer by Medical Oncologist at Cleveland Clinic (February 22, 2017)
Although the results from the phase II CABOSUN trial were intriquing, I would not consider cabozantinib as first line therapy for patients with intermediate or poor-...